High-Impact Movers for June 21st
Portfolio Pulse from ryanfaloona@benzinga.com
AHI signed a letter of intent with UAE-based e-Script Medicine Management Company Pharmak Direct. Eightco Holdings Inc. (OCTO) raised its revenue guidance to $73 million for FY2023. Chemomab Therapeutics (CMMB) reported positive data from a secondary analysis of a Phase 2a liver fibrosis trial in NASH patients at EASL 2023.
June 21, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AHI signed a letter of intent with UAE-based e-Script Medicine Management Company Pharmak Direct, potentially expanding its market reach.
The partnership with Pharmak Direct could help AHI expand its market reach and increase its revenue, which may positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Chemomab Therapeutics (CMMB) reported positive data from a secondary analysis of a Phase 2a liver fibrosis trial in NASH patients at EASL 2023.
The positive data from the Phase 2a liver fibrosis trial indicates potential progress in NASH treatment, which could positively impact CMMB's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
Eightco Holdings Inc. (OCTO) raised its revenue guidance to $73 million for FY2023, indicating strong growth prospects.
The increased revenue guidance for FY2023 suggests that OCTO is expecting strong growth, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100